Sign in
CompletedPhase 1/2

Investigating the Efficacy of Ergothioneine to Delay Cognitive Decline (Pilot)

Key facts

Who runs it
National University Hospital, Singapore
Where
Singapore1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 1/2
People taking part
19 people enrolled
Started
1 Aug 2019
Ended
31 Dec 2023
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • L-ergothioneine
  • Placebo
Record updated
11 June 2025

Who can take part

Age
60 years to 90 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Elderly individuals 60 - 90 years of age
  • Chinese ethnicity (from other local cohort studies)
  • Demonstrate amnestic mild cognitive impairment (assessed by panel of psychiatrists)
  • Independent and able to travel to study site without assistance
  • No other severe underlying conditions or terminal illnesses
  • Capable of understanding the study and requirements and able to provide informed consent to participate
  • Willing to commit to the year-long study, comply with study administration and periodic blood and urine sampling

Who cannot take part

  • Any intolerance to lactose, and/or allergies to mushrooms
  • History of cardiovascular complications, diabetes, hypertension or hypercholesterolemia, or other pre-existing condition that may prevent them from completing the study
  • Evidence of anaemia or other significant haematological conditions
  • History or mental illness, depression or other underlying psychiatric illnesses
  • History of drug or alcohol abuse
  • Inability to understand the risks and requirements of the study for any reason
  • Involvement in another study requiring administration of an investigational compound in the past 30 days
  • Subjects whose blood analysis reveal and extremes of liver or kidney function markers (from baseline screening)
  • Deemed unfit for any reason as determined by the principal/co-investigator

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

With the growing burden of dementia (including Alzheimer's disease), and the lack of efficacious therapies, there is an urgent need to identify new therapeutics.

Read full original descriptionShow less

Ergothioneine (ET) is a naturally occurring thiol derivative of histidine, obtained solely through diet and is able to accumulate in the body and brain, through the action of a specific transporter, OCTN1. In addition to a wide variety of in vitro and in vivo (animal) studies demonstrating the antioxidant, anti-inflammatory properties of ET, several studies have demonstrated the neuroprotective potential of ET in various cell and animal models.

Based on the ability of ET to counteract the underlying pathology of AD dementia, it is hypothesize that ET supplementation may prevent cognitive decline, especially in individuals at risk of cognitive impairment. This will be assessed using a randomized, double blinded, placebo-controlled, intervention study to test the ability of ET to delay or reverse cognitive impairment in elderly individuals with mild cognitive impairment.

The 2 groups in the trial

  • ErgothioneineExisting treatment, for comparison

    Subjects will consume 25mg ergothioneine (capsule), 3 times weekly (Monday, Wednesday, and Friday) for a total of 52 weeks.

    Treatment: L-ergothioneine

  • PlaceboPlacebo, for comparison

    Subjects will be given placebo (99% microcrystalline cellulose, 1% magnesium stearate; capsule), 3 times weekly (Monday, Wednesday, and Friday) for a total of 52 weeks.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Pilot Study to Investigate the Efficacy of Ergothioneine to Delay Cognitive Decline in Mild Cognitively Impaired Subjects
Publications
Record updated
11 June 2025